Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine ...

Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine ...

to discuss the Company’s fourth quarter and full year 2024 financial results which will be released before the stock market opens. The call will be simultaneously webcast on Viking's investor ...

today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. About Viking Therapeutics, Inc. Viking ...

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine ...